Paid Clinical Trials New Mexico
Discover 422 paid clinical trials in New Mexico. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Amplitude Titration to Improve ECT Clinical Outcomes
Sponsor:
University of New Mexico
Location:
Code:
NCT05699226
Conditions
Depression
ECT
Cognitive Change
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Soterix Medical Incorporated 4x1 adapter
Traditional ECT device
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04310020
Conditions
Recurrent Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Biospecimen Collection
Computed Tomography
Hypofractionated Radiation Therapy
Magnetic Resonance Imaging
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05773274
Conditions
Metastatic Midgut Neuroendocrine Tumor
Metastatic Midgut Neuroendocrine Tumor G1
Metastatic Midgut Neuroendocrine Tumor G2
Unresectable Midgut Neuroendocrine Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Everolimus
Lutetium Lu 177 Dotatate
Quality-of-Life Assessment
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Sponsor:
Seagen Inc.
Location:
Code:
NCT06003231
Conditions
Carcinoma, Squamous Cell of Head and Neck
Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Endometrial Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
disitamab vedotin
Enlighten Study: The EV-ICD Post Approval Registry
Sponsor:
Medtronic
Location:
Code:
NCT06048731
Conditions
Ventricular Arrhythmia
Tachycardia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Defibrillation using EV-ICD
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Sponsor:
Inhibrx Biosciences, Inc
Location:
Code:
NCT06295731
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INBRX-106
Pembrolizumab
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Sponsor:
Pfizer
Location:
Code:
NCT06163326
Conditions
Vitiligo
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Ritlecitinib
Ritlecitinib 100 mg
Placebo